Samsung Biologics Reports First Quarter 2022 Financial Results

CD ComputaBio Unveils Protein Structure Modeling Service for Drug Development

Untargeted Lipidomics Now Available with Creative Proteomics’s New Cutting-Edge Lipidomics Platform

Pronalyse Unveils Gene Therapy Products Characterization Service to Safely Accelerate Drug Development

Creative Proteomics Metabolomics Expands Service Offering with the Launch of Plant Untargeted Metabolomics Service

Global Biologics CDMO Market is set to witness a CAGR of 15% to reach $35 billion by 2025, driven by the growing biopharmaceutical end market

Rapidly expanding pipelines of cell & gene therapies and new vaccines and significant VC fundings are driving the growth of the Biologics CDMO market.

Biofourmis Receives Significant Growth Investment from General Atlantic to Propel Company to Unicorn Status

With this investment, Biofourmis plans to scale up its virtual care offerings. This includes delivering personalized and predictive in-home care to a growing number of acutely ill patients and expanding its recently announced virtual specialty care services, Biofourmis Care, to those patients with complex chronic conditions. In parallel, Biofourmis plans to fund clinical trials to advance the development of digital therapies that work in conjunction with high-value drugs to improve efficacy, while forming strategic partnerships with companies in the digital health and virtual-first care ecosystems.

Onyx Scientific opens second site and expands small molecule CMC services

WCG Selected as the Institutional Review Board of Record for The Michael J. Fox Foundation’s Parkinson’s Progression Markers Initiative

PPMI is designed to identify biological markers and clinical changes associated with Parkinson’s disease risk, onset, and progression.

CTL Amedica Corp. Awarded U.S. Patent for KLIMT™ Expandable Lumbar Interbody Fusion Cage Design

The US Patent and Trademark Office has awarded CTL Amedica Corporation US PAT 11, 291.559, an official patent for the KLIMT™ Expandable Lumbar Interbody Fusion Cage design. The KLIMT™ features proprietary, 3D-printed, expandable technology.

New Genedata Screener 19.0 Further Accelerates Biotherapeutics R&D

The latest version of Genedata Screener features smart workflow automation and fit-for-purpose, big data visualizations that enable fast, functional characterization of tens of thousands of candidate molecules.

MicrobioSeq Introduces Fungal Whole-Genome De Novo Sequencing Platform to Facilitate Microbial Research

CD Genomics Releases Human Mitochondrial DNA Sequencing for Disease Research and Biodiversity Assessment

“International Conference on Veterinary Science” (VET 2022)

Vyasa Layar Now Available on SAP® Store

Vyasa, an innovative provider of highly scalable deep learning AI analytics software for healthcare, life sciences, and business applications, announced today the availability of its Vyasa Layar offering on SAP® Store, the online marketplace for SAP and partner offerings. Through Vyasa Layar data fabric, users can connect to Sybase® and to SAP Business Technology Platform (SAP BTP) with SAP HANA® to create a unified data experience regardless of data format or storage location.

Tjoapack doubles packaging capacity with completed Netherlands facility expansion

Global pharmaceutical contract packaging organisation (CPO), Tjoapack has announced the completion of its expansion plans following a €10m+ plus investment at its Etten-Leur facility in the Netherlands.

Rho Appoints Peter Schmidt, Ph.D., as SVP, Government Partnerships, Executive Committee Member

Rho Appoints Peter Schmidt, Ph.D., as SVP, Government Partnerships, Executive Committee Member Former Vice Dean at East Carolina University’s Brody School of Medicine brings scientific and strategic expertise to lead the federally funded clinical research enterprise of this international CRO. Research Triangle Park, NC – April 19, 2022 – Rho, a global full-service contract research organization (CRO) with a proven track record of drug development success, has appointed Peter Schmidt, Ph.D., as Senior Vice President, Government Partnerships of Rho’s Federal Systems Division. For over 30 years, Rho has worked closely with NIH/NIAID and other federal departments on groundbreaking clinical trial and epidemiologic studies, including the LEAP peanut allergy study. “I am thrilled to welcome Dr. Schmidt to Rho," said Dr. Laura Helms Reece, CEO, Rho. “He is a preeminent neuroscientist and recognized leader across federal, commercial and academic arenas. His expertise in clinical research is remarkable, and his command of central nervous system, infectious disease, and other indications is a great fit with Rho’s focus in those areas. I am eager to work with Dr. Schmidt as he brings exciting strategic and scientific leadership to our federal business. His experience and judgment will be great additions to our Executive Committee.”

Recipharm completes US biologics acquisitions

Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announces the closing of its acquisitions of advanced therapy CDMO Arranta Bio and virotherapy CDMO Vibalogics.

Bora Pharmaceuticals to expand operations with $10m+ investment

Huateng Pharma Develops COVID-19 Drug Paxlovid & Ensitrelvir Intermediates

Huateng Pharma is a full-service Contract Development Manufacturing Organizations (CDMO) for pharmaceutical intermediates, including paxlovid and ensitrelvir intermediates.